Pune, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Biomarkers Market Size & Growth Analysis:
“According to SNS Insider, the Global Biomarkers Market was valued at USD 67.92 billion in 2023 and is projected to reach USD 184.80 billion by 2032, growing at a steady CAGR of 11.78% over the forecast period from 2024 to 2032.”
Biomarkers market is mainly fueled by the rising application of biomarkers in precision medicine, the growing incidence of chronic diseases, and advancements in biomarker-based diagnostics technology. With increasing utility in drug discovery, personalized treatment modalities, and disease diagnosis, the demand for biomarkers increases across the world.
Get a Sample Report of Biomarkers Market@ https://www.snsinsider.com/sample-request/3257
Key Biomarkers Companies Profiled
- F. Hoffmann-La Roche AG – Elecsys Biomarkers, Cobas Diagnostics
- Epigenomics AG – Epi proColon, Epi proLung
- Abbott – ARCHITECT Biomarker Assays, Alinity System
- Thermo Fisher Scientific Inc. – ProQuantum Immunoassays, TaqMan Assays
- General Electric – Discovery Biomarker Solutions
- Eurofins Scientific – Biomarker Assay Services, Genomic Biomarkers
- Johnson & Johnson Services, Inc. – Janssen Biomarker Research
- QIAGEN – QIAseq Targeted RNA Panels, QIAamp DNA Kits
- Bio-Rad Laboratories, Inc. – Bio-Plex Multiplex Assays, ddPCR Biomarkers
- Siemens Healthineers AG – Atellica IM Biomarkers, ADVIA Centaur
- Merck KGaA – MILLIPLEX Assays, SMC Biomarker Assays
- PerkinElmer Inc. – AlphaLISA Biomarker Assays, DELFIA Kits
- Agilent Technologies, Inc. – SurePrint G3 Microarrays, AssayMAP Technology
- Revvity – LABScreen, Luminex Multiplex Assays
- Laboratory Corporation of America Holdings – Biomarker Testing Services
- Charles River Laboratories – Biomarker Discovery & Validation Services
- BIOMÉRIEUX – VIDAS Biomarkers, VITEK Biomarkers
- JSR Corporation – Biomarker Antibodies & Reagents
- Quanterix – Simoa Biomarker Detection Technology
- MESO SCALE DIAGNOSTICS LLC. – MULTI-ARRAY Technology Biomarkers
Biomarkers Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 67.92 billion |
| Market Size by 2032 | US$ 184.80 billion |
| CAGR | CAGR of 11.78% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
Segmentation Insights
By Product, the consumables segment led the market in 2023.
The consumables segment led the market because it plays a vital role in clinical use, research, and diagnosis. Consumables such as reagents, assay kits, and biomarker test materials are highly utilized in labs for repeated assays in biomarker detection and analysis. The continual development of assay technologies and growth in demand for quick and efficient diagnostic products also fuel the development of this segment. Moreover, the increasing number of biomarker-based research studies, clinical trials, and precision medicine projects has considerably boosted the consumption of biomarker consumables. In contrast, the services segment is growing at a speedy pace as pharmaceutical and biotech firms more and more depend on outsourced services for biomarker validation, regulatory requirements, and analytical testing to speed up drug discovery and development.
By Type, safety biomarkers dominated the market, while efficacy biomarkers are poised for rapid expansion.
Safety biomarkers accounted for the largest revenue percentage in 2023, courtesy of their immense importance in clinical and preclinical research. Biomarkers are greatly utilized to predict drug toxicity, track adverse events, and ascertain patient safety before new therapeutics are approved for sale. Regulatory agencies, such as the FDA and EMA, highlight the application of safety biomarkers in drug development to minimize the risk of adverse effects and maximize drug efficacy. Conversely, efficacy biomarkers are increasingly becoming popular as they offer significant information on treatment response and disease progression. Targeted therapy and personalized medicine heavily rely on these biomarkers to enable healthcare providers to assess the efficacy of a particular treatment. As the importance of personalized healthcare solutions continues to grow, the efficacy biomarkers segment is likely to see a significant increase in the future.
By Application, drug discovery & development emerged as the leading segment, with diagnostics expected to expand rapidly.
The drug discovery & development segment dominated the biomarkers market in 2023, driven by the increased adoption of biomarkers in pharma research and clinical trials. Biomarkers have an important function to play in discovering new targets for drugs, improving patient selection for clinical trials, and foretelling responses to treatment, eventually resulting in more effective and economical drug development. Pharmaceuticals are increasingly using biomarkers to optimize the drug discovery process, improve precision medicine initiatives, and enhance regulatory approval rates. At the same time, the diagnostics segment is expected to develop at the fastest rate with growing demand for non-invasive diagnostic tools and early disease detection methods. Biomarker-based diagnostics are transforming disease screening, especially in oncology, infectious diseases, and neurodegenerative diseases. The growth of sophisticated biomarker-based tests, such as liquid biopsies and genomic profiling, is anticipated to fuel the swift growth of this segment.
By Disease, the cancer segment remained dominant, while immunological diseases are expected to witness the highest growth.
Cancer was the largest disease segment within the biomarkers market in 2023, driven by the rising incidence of different cancers and the need for biomarker-guided cancer diagnostics and treatments. Biomarkers find extensive applications in oncology to detect cancer early, predict its course, and monitor the outcome of treatments. Precision oncology, which relies on biomarkers to personalize cancer treatment according to personal genetic signatures, is heavily fueling this segment's expansion. With innovations in liquid biopsy platforms and companion diagnostics, cancer biomarker usage is growing tremendously, resulting in enhanced patient care. Conversely, the immunological diseases segment will experience the most rapid growth with rising research in autoimmune diseases, inflammatory diseases, and immunotherapy. The increasing disease burden of rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease is driving demand for biomarkers that support early diagnosis and optimization of treatment.
Need any customization research on Biomarkers Market, Enquire Now@ https://www.snsinsider.com/enquiry/3257
Biomarkers Market Segmentation
By Product
- Consumables
- Services
- Software
By Type
- Safety Biomarkers
- Efficacy Biomarkers
- Predictive Biomarkers
- Surrogate Biomarkers
- Pharmacodynamic Biomarkers
- Prognostics Biomarkers
- Validation Biomarkers
By Application
- Diagnostics
- Drug discovery & development
- Personalized Medicine
- Disease Risk Assessment
- Others
By Disease
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
Regional Analysis
North America dominated the biomarkers market in 2023, capturing the highest market share.
Drivers of this leadership are sophisticated healthcare infrastructure, robust government support for biomarker research, and a well-developed pharmaceutical industry fueling biomarker uptake. The availability of top market players and supportive regulatory policies also contribute to market growth in the region. Moreover, the growing emphasis on precision medicine and targeted therapies is fueling demand for biomarkers in different applications such as cancer diagnosis, neurological disorders, and cardiology.
The Asia-Pacific region is expected to emerge as the growth leader for biomarkers during the forecast period. Increased healthcare expenditures, growing biotechnology and pharma sectors, and rising disease burden are principal drivers driving demand. China, India, and Japan are the leaders in adopting biomarkers, especially in the fields of oncology, infectious diseases, and chronic disease diagnostics. Further, government programs backing precision medicine and clinical research are likely to spur growth in the region. Increased access to advanced diagnostic equipment, biomarker-targeted treatment awareness, and enhanced healthcare spending are also driving the biomarkers market in Asia-Pacific.
Buy a Single-User PDF of Biomarkers Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/3257
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Diseases Requiring Biomarkers (2023)
5.2 Biomarker Testing Adoption Trends (2020-2032), by Region
5.3 Biomarker-Based Diagnostic and Drug Development Trends (2023)
5.4 Healthcare Spending on Biomarker-Based Diagnostics and Therapies (2023), by Region
6. Competitive Landscape
7. Biomarkers Market by Product
8. Biomarkers Market by Type
9. Biomarkers Market by Application
10. Biomarkers Market by Disease
11. Regional Analysis
12. Company Profiles
13. Use Cases and Best Practices
14. Conclusion
Access Complete Report Details of Biomarkers Market Analysis & Outlook 2024-2032@ https://www.snsinsider.com/reports/biomarkers-market-3257
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
